Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck
- PMID: 22180262
- DOI: 10.1002/hed.21971
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck
Abstract
Background: This phase II study tested the addition of the oral epidermal growth factor receptor gefitinib to multiagent concurrent chemoradiotherapy regimen in head and neck squamous cell cancer (HNSCC).
Methods: Patients with stage III-IV HNSCC received hyperfractionated radiation (72-74.4 Gy at 120 cGy twice daily), with concurrent 96-hour infusions of cisplatin 20 mg/m(2) /day and fluorouracil 1000 mg/m(2) /day given during weeks 1 and 4. Daily gefitinib 250 mg was started on day 1 of radiation and continued for 2 years. Results were retrospectively compared with our previous study using identical chemoradiotherapy without gefitinib.
Results: Sixty patients were enrolled in the study; 80% had stage IV disease and 68% had oropharyngeal primary tumors. The full course of gefitinib was not tolerated by 42%; there were 5 treatment-related deaths (8%). With a median follow-up of 54 months, 2- and 3-year overall survival estimates were 80% and 71%, respectively. Projected distant metastatic control at 2 and 3 years was 88%. When compared with our historical cohort, acute toxicities including renal dysfunction and unplanned rehospitalization were worse in the study patients. Projected outcome estimates did not differ between the 2 cohorts.
Conclusions: Addition of gefitinib to concurrent chemoradiotherapy was difficult to complete, did not improve outcomes, and increased toxicity.
Copyright © 2011 Wiley Periodicals, Inc.
Similar articles
-
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.J Clin Oncol. 2004 Aug 1;22(15):3061-9. doi: 10.1200/JCO.2004.01.108. J Clin Oncol. 2004. PMID: 15284256 Clinical Trial.
-
Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.Head Neck. 2015 Nov;37(11):1583-9. doi: 10.1002/hed.23794. Epub 2014 Oct 29. Head Neck. 2015. PMID: 24909549 Clinical Trial.
-
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.J Clin Oncol. 2002 Mar 1;20(5):1405-10. doi: 10.1200/JCO.2002.20.5.1405. J Clin Oncol. 2002. PMID: 11870186
-
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.Eur Arch Otorhinolaryngol. 2012 Oct;269(10):2157-67. doi: 10.1007/s00405-012-1998-3. Epub 2012 Mar 22. Eur Arch Otorhinolaryngol. 2012. PMID: 22437252 Review.
-
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?Anticancer Drugs. 2018 Apr;29(4):287-294. doi: 10.1097/CAD.0000000000000595. Anticancer Drugs. 2018. PMID: 29420335 Review.
Cited by
-
Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Clin Med Insights Ther. 2013;2013(5):10.4137/CMT.S10409. doi: 10.4137/CMT.S10409. Clin Med Insights Ther. 2013. PMID: 24273416 Free PMC article.
-
EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication.Oncotarget. 2018 Jun 22;9(48):28965-28975. doi: 10.18632/oncotarget.25656. eCollection 2018 Jun 22. Oncotarget. 2018. PMID: 29989001 Free PMC article.
-
Molecular biology and immunology of head and neck cancer.Surg Oncol Clin N Am. 2015 Jul;24(3):397-407. doi: 10.1016/j.soc.2015.03.002. Epub 2015 Apr 20. Surg Oncol Clin N Am. 2015. PMID: 25979390 Free PMC article. Review.
-
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.Clin Cancer Res. 2020 Nov 15;26(22):5860-5868. doi: 10.1158/1078-0432.CCR-20-2276. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943457 Free PMC article. Clinical Trial.
-
Radiotherapy plus EGFR inhibitors: synergistic modalities.Cancers Head Neck. 2017 Jan 18;2:2. doi: 10.1186/s41199-016-0020-y. eCollection 2017. Cancers Head Neck. 2017. PMID: 31093349 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials